Skip to content
Recall Observatory FDA recall evidence

Drug product

BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04

D-0042-2024

September 25, 2023

Class I

Product summary

Firm
Scynexis, Inc.
Event
Event 93113
Status
Completed
Classification
Class I
Quantity
17,376
Official record key
drug-enforcement:D-0042-2024

Official wording

Reason: Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).

Code information: Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025

Distribution pattern: Nationwide in the US.

Derived failure modes

  • Unknown

    reason.no_named_rule · v1.0.0

    Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).